Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in lower-risk MDS with ring sideroblasts
NCT05181592Phase 3Active, not recruiting
- Sponsor
- GWT-TUD
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 3 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by GWT-TUD. Started Oct 2021; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05181592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181592.